Research Alliance Holdings IV LLC disclosed a 17.0% beneficial stake in Research Alliance Corporation IV. The filing, dated July 21, 2026, follows the SPAC’s July 14, 2026 IPO and a concurrent private placement to the sponsor. The move cements the sponsor’s significant influence as the company seeks an initial business combination.
Investor Intent
RA Holdings IV says it invested for long-term purposes and may buy or sell more securities over time. The sponsor agreed to "vote their shares in favor of any proposed initial business combination" and "not to redeem any shares in connection with a shareholder vote" on that deal.
Matthew Hammond, the sponsor’s manager and the SPAC’s CEO and director, will stay closely involved in strategy discussions. The stake, along with these voting commitments, positions the sponsor to help steer the path to a merger.
Investor's Background
Research Alliance Holdings IV LLC is the sponsor of Research Alliance Corporation IV, a special purpose acquisition company. The sponsor is affiliated with RA Capital Management, L.P., a healthcare-focused investment firm known for backing biotechnology and life sciences companies. RA Capital typically invests across public and private healthcare assets and often supports growth through follow-on financing.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.